NIH partners with Vtesse on Cyclodextrin clinical trial!

Thank you to all of DART’s supporters. We have great news! The National Institutes of Health announced last Wednesday, while Andrew was getting his 16th monthly dose of Cyclodextrin (see photo), that the NIH has selected pharma company Vtesse to partner on the further development of treatments for NPC, starting with the continuation of the Cyclodextrin clinical trial.

Andrew-Cyclo_Dose14

You can read the NIH press release here including a mention of DART and other NPC research foundations: http://www.nih.gov/news/health/jan2015/ncats-07.htm

Vtesse’s press release is here:
http://www.vtessepharma.com/

We also want to thank the many NPC researchers at the NIH and elsewhere for their tireless work on behalf of all of the children, and welcome Vtesse into our family.

Be Sociable, Share!
Posted in Announcements, DART News, Niemann-Pick Type C News, Research News